NIV-NAVA in Infants With Severe Bronchiolitis, a Pilot Multicenter Randomized Controlled Trial (NAVIGATE)
Non-invasive Ventilation With NAVA in Infants With Severe Bronchiolitis. A Multicenter Pilot Open Label Pragmatic Randomized Controlled Trial (NAVIGATE Trial)
Severe bronchiolitis is a common lung infection in babies that can cause serious breathing problems and often leads to hospitalization in pediatric intensive care units (PICUs). Many infants need special breathing support, usually through non-invasive methods like high-flow oxygen or continuous airway pressure. However, these methods don't always work, and about one in four infants end up needing a breathing tube (intubation), which comes with more risks and a longer recovery.
A newer breathing support method called NIV-NAVA (non-invasive ventilation with neurally adjusted ventilatory assist) may help. It uses signals from the baby's diaphragm to adjust the support in real-time, making breathing easier and possibly reducing the need for intubation. While early results are promising, no high-quality clinical trial has yet tested if NIV-NAVA is better than standard non-invasive support.
This study is a pilot trial - a small-scale version of a larger future study - happening in four PICUs across Canada. It will include 90 babies under 2 years old with severe bronchiolitis who need more support than standard methods provide. Half will receive NIV-NAVA, and half will receive the usual care.
The main goal of this pilot is to check if a larger trial is doable: Can we recruit enough babies? Can the PICU teams stick to the treatment plan? Can we collect the right information? The full study will eventually look at whether NIV-NAVA really lowers the number of babies who need intubation and improves recovery.
This research is led by a team of pediatric experts and could pave the way for better care for thousands of infants with severe breathing problems.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Goal(s) / Research Aims The primary objective of this multicenter pilot RCT is to determine the feasibility of a definitive multicenter RCT that will evaluate whether NIV-NAVA is superior to conventional NIV in infants with severe bronchiolitis who are not adequately supported by HFNC or CPAP. The primary hypothesis is that the pilot RCT will confirm the feasibility of the final trial.
Methods / Approaches This is an investigator-led, multicenter, randomized, controlled, open-label, pragmatic pilot trial conducted in four Canadian pediatric intensive care units (PICUs) with varying levels of experience with NIV-NAVA, supported by the Canadian Critical Care Trials Group (CCCTG).
Ninety infants younger than 2 years old who are admitted to the PICU with a clinical diagnosis of bronchiolitis, who require NIV support greater than CPAP/HFNC, and who have no exclusion criteria will be randomized 1:1 between NIV-NAVA and conventional NIV management.
The pilot trial's feasibility outcomes are the recruitment rate (the primary outcome), adherence to the intervention, and completion of the definitive trial's outcome measures. The primary outcome of the future definitive RCT is the intubation rate. Secondary outcomes will include respiratory distress evolution, comfort, duration of ventilatory support, PICU and hospital length of stay, nutrition and sedation, complication rates, post-PICU functional outcomes, carbon footprint, and cost-effectiveness analysis.
Expertise. An experienced, multidisciplinary team of senior, mid, and early career clinician scientists with unique expertise in pediatric NIV, trial methodology, pediatric respirology, and PICU research is leading this project.
Expected Outcomes. We expect this pilot trial to confirm the feasibility of a definitive trial on NIV-NAVA in severe bronchiolitis. As the first RCT in this understudied field, it will provide much-needed evidence on the most effective strategy for reducing intubation rates in infants with severe bronchiolitis.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Guillaume Emeriaud, MD PhD
- Número de teléfono: 5143454708
- Correo electrónico: guillaume.emeriaud@umontreal.ca
Copia de seguridad de contactos de estudio
- Nombre: Lucy Clayton, MSc
- Correo electrónico: lucy.clayton.hsj@ssss.gouv.qc.ca
Ubicaciones de estudio
-
-
Alberta
-
Calgary, Alberta, Canadá
- Alberta Children's Hospital
-
Contacto:
- Laurie Lee, NPS PhD
- Número de teléfono: 4032206546
- Correo electrónico: laurie.lee@ucalgary.ca
-
-
Ontario
-
Ottawa, Ontario, Canadá
- CHEO
-
Contacto:
- Dayre McNally, MD
- Número de teléfono: 6137377600
- Correo electrónico: dmcnally@cheo.on.ca
-
-
Quebec
-
Montreal, Quebec, Canadá
- Montreal Children's Hospital
-
Contacto:
- Patricia Fontela, MD PhD
- Número de teléfono: 22855 5144124400
- Correo electrónico: patricia.fontela.med@ssss.gouv.qc.ca
-
Montreal, Quebec, Canadá
- CHU Sainte Justine
-
Contacto:
- Guillaume Emeriaud, MD PhD
- Número de teléfono: 5143454708
- Correo electrónico: guillaume.emeriaud@umontreal.ca
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Infants younger than 2 years old
- admitted to the PICU (or managed by the PICU team while awaiting PICU admission)
- with a clinical diagnosis of bronchiolitis according to the treating team
- requiring NIV support higher than CPAP/HFNC according to the treating team, a criteria present for less than 8 hours.
Exclusion Criteria:
- imminent intubation criteria
- refusal by the physician in charge
- chronic home ventilation
- hemodynamic instability requiring vasopressors
- contraindication to NIV or to gastric tube insertion
- patients in whom a limitation of life-support treatment is considered
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: NIV-NAVA arm
Installation of an Edi catheter. Ventilation with NIV-NAVA as long as a bi-level NIV support is needed. |
Non-invasive support using NAVA technology |
|
Sin intervención: Control arm (usual care)
Ventilation according to the clinical team. No NAVA ventilation allowed. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recruitment rate
Periodo de tiempo: from initiation to the end of the 6-month study enrolment period
|
% of eligible patients (identified by screening) who are included in the study at each site and overall |
from initiation to the end of the 6-month study enrolment period
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
adherence to the intervention
Periodo de tiempo: during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
|
In the NAVA arm : % of patients who receive at least 2 hours of NIV-NAVA support, within 2 hours after randomization. In control arm: absence of NAVA use |
during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
|
|
completion of the definitive trial outcomes
Periodo de tiempo: from initiation to the end of the 6-month study enrolment period
|
completion of the definitive trial outcomes : measurement of intubation rate, duration of ventilatory support, length of PICU and hospital stays |
from initiation to the end of the 6-month study enrolment period
|
|
Evolution of the respiratory distress mWCAS score
Periodo de tiempo: at randomization, and after 2, 6, and 24 hours
|
Evolution of mWCAS |
at randomization, and after 2, 6, and 24 hours
|
|
Evolution of the respiratory distress ROX-HR score
Periodo de tiempo: at randomization, and after 2, 6, and 24 hours
|
Evolution of ROX-HR scores |
at randomization, and after 2, 6, and 24 hours
|
|
Evolution of the comfort score
Periodo de tiempo: at randomization, and after 2, 6, and 24 hours
|
Evolution of the comfort score (FLACC) |
at randomization, and after 2, 6, and 24 hours
|
|
Capacity to assess the evolution at 3 months post PICU
Periodo de tiempo: 3 months post PICU discharge
|
Percentage of patients with assessment of PICS-p at 3 months post discharge |
3 months post PICU discharge
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Guillaume Emeriaud, MD PhD, CHU Sainte Justine, Université de Montréal
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- MP-21-2027-10447
- 583747 (Otro número de subvención/financiamiento: CIHR)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
This is a pilot study. If the pilot shows feasibility of a larger trial with no change in the protocol, we may continue the trial with the same protocol and enroll the subjects from the pilot within the larger trial (Vanguard).
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .